Table 1.
Clinical characteristics of the 64 female SLE patients in this study, including current treatment and prevalence of the fulfilled SLICC classification criteria for SLE.
| Clinical characteristics | |
|---|---|
| Age [years], median (range) | 39 (18–52) |
| Disease duration [years], median (range)a | 11 (0–26) |
| SLEDAI-2 K, median (range) | 2 (0–18) |
| SDI, median (range) | 0 (0–5) |
| Smoking, n (%)b | 23 (36 %) |
| Treatment | |
| Hydroxychloroquine, n (%) | 51 (80 %) |
| Other DMARDs except hydroxychloroquine, n (%) | 38 (59 %) |
| Prednisolone, n (%) | 50 (78 %) |
| Prednisolone daily dose [mg/day], median (range) | 5 (0–25) |
| Antihypertensive medication, n (%) | 19 (30 %) |
| SLICC criteria for SLE classification | |
| Acute cutaneous lupus, n (%) | 46 (72 %) |
| Chronic cutaneous lupus, n (%) | 16 (25 %) |
| Oral or nasal ulcers, n (%) | 27 (42 %) |
| Non scarring alopecia, n (%) | 23 (36 %) |
| Joint disease, n (%) | 55 (86 %) |
| Serositis (%) | 27 (42 %) |
| Renal manifestations, n (%) | 24 (38 %) |
| Neurological manifestations, n (%) | 9 (14 %) |
| Hemolytic anemia, n (%) | 3 (5 %) |
| Leukopenia or lymphopenia, n (%) | 39 (61 %) |
| Thrombocytopenia, n (%) | 19 (30 %) |
| ANA, n (%) | 63 (98 %) |
| Anti-dsDNA, n (%) | 38 (59 %) |
| Anti-Sm, n (%) | 11 (17 %) |
| aPL, n (%)c | 20 (31 %) |
| Low complement, n (%) | 38 (59 %) |
| Positive Direct Coombs test, n (%) | 2 (3 %) |
SLE = Systemic lupus erythematosus, SLICC = Systemic Lupus International Collaborating Clinics, SLEDAI-2 K = Systemic Lupus Erythematosus Disease Activity Index 2000, SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, DMARDs = Disease-modifying antirheumatic drugs, ANA = Antinuclear antibodies, Anti-dsDNA = Anti-double stranded DNA antibodies, Anti-Sm = Anti-Smith, aPL = Antiphospholipid antibodies.
Duration between SLE diagnosis and date of the MRI scan.
Current or history of smoking.
Positive serology in any of the following: Lupus Anticoagulant, anticardiolipin antibodies or anti-β2 glycoprotein I antibodies.